Compare BZH & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | CDNA |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | 650 |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.0M | 1.0B |
| IPO Year | 1994 | 2014 |
| Metric | BZH | CDNA |
|---|---|---|
| Price | $20.28 | $19.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $32.00 | $26.67 |
| AVG Volume (30 Days) | 403.3K | ★ 768.6K |
| Earning Date | 01-29-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | 1.22 |
| Revenue | ★ $2,371,555,000.00 | $357,998,000.00 |
| Revenue This Year | $7.40 | $14.11 |
| Revenue Next Year | $12.09 | $11.75 |
| P/E Ratio | ★ $13.34 | $16.03 |
| Revenue Growth | 1.77 | ★ 14.46 |
| 52 Week Low | $17.37 | $10.96 |
| 52 Week High | $29.30 | $25.95 |
| Indicator | BZH | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 58.23 |
| Support Level | $20.00 | $19.01 |
| Resistance Level | $22.04 | $20.61 |
| Average True Range (ATR) | 0.61 | 0.80 |
| MACD | -0.24 | -0.11 |
| Stochastic Oscillator | 6.07 | 45.12 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.